Email: cspc@cspc.cn
Media
News Center
Jul. 17
2026
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR TRASTUZUMAB ENVEDOTIN INJECTION ACCEPTED BY THE NMPA
Jul. 16
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SYS6043 FOR THE TREATMENT OF PLATINUM-RESISTANT ADVANCED OVARIAN CANCER, PRIMARY PERITONEAL CANCER, AND FAL
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) FOR THE TREATMENT OF EPITHELIOID HAEMANGIOENDOTHELIOMA OFFICIALLY IN
Jul. 14
VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) AND ANBENITAMAB (KN026) GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE FIRS
Jul. 07
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI
Jul. 02
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY OF SYH2095 TABLETS AS A MONOTHERAPY OR IN COMBINATION REGIMENS FOR THE TREATMENT OF ADVANCED MALIGNANT TUMOURS O
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
